



### Who we are - Austrade

**Austrade** is the Australian Government's trade promotion and investment attraction and facilitation agency.

In cooperation with State and Territory governments, Austrade provides confidential assistance and services.

National coordination of Australian government investment services

Advice on Australian government programs and approval processes

Introductions to key government agencies, including the State and Territory governments

Market intelligence and investment opportunities

Information on the Australian business and regulatory environment

Identification of suitable investment locations and partners, and site visit arrangements



#### **ENERGY**

Hydrogen Renewables (Storage, Wind, Solar) Energy Tech



**RESOURCES** 

Critical minerals Oil and gas **Bulk commodities** Resources Tech



#### **CIRCULAR ECONOMY**

Waste Processing (E-Waste, Plastic, Building Materials) Waste to Energy



#### **DIGITECH**

Fintech Cyber security Enterprise technology Immersive technology Edtech



Civic & transport infrastructure Future Transport/Smart cities

Tourism Infrastructure



#### **HEALTH INDUSTRIES**

Biotechnology **Pharmaceuticals** Medical devices Digital health



#### **AGRI-FOOD**

Advanced food & beverage processing Aquaculture Intensive horticulture Agtech



#### **DEFENCE & SPACE**

**Automation & Robotics** Space

### A hybrid public-private healthcare system

Australia's hybrid public-private healthcare system supports a dynamic research and innovation ecosystem that attracts investment and expertise from around the word.



#### **Universal services:**

Medicare is Australia's universal health insurance scheme



#### **Private insurance:**

Health companies own 630 hospitals with 33,000 beds (1/3 the total)



### **Subsidised pharma:**

covers 5,200 medicines



### **Funded research:**

inc. the A\$20 billion Medical Research Future Fund and the National Health and Medical Research Council (NHMRC)



### **High-energy innovation:**


top-ranking universities, medical precincts



### Niche expertise:

oncology, neurology, tropical medicine, medical devices and diagnostics Quality. Speed. Cost.

Australia is an ideal location for conducting clinical trials





Sophisticated health and medical research and environment



Quality transferable data



Cost-efficient




Rapid approvals and robust regulatory framework



An ethnically diverse patient population

#### Clinical trials

# Clinical trials are part of a robust and diverse health and medical research ecosystem in Australia





# Whole-of-government support for clinical trials



and national action to ensure an efficient, high-quality and vibrant clinical trials environment



## A \$20 billion endowment fund

Medical Research Future Fund (MRFF) supports translational research and commercialisation

Includes \$750 million **Clinical Trials Activity Initiative** over the next 10 years



## National Mutual Acceptance (NMA)

a system for mutual acceptance of scientific and ethical review for multi-centre clinical trials conducted across multiple states



#### Clinical trials

# Whole-of-government support for clinical trials

National resources to support getting started australianclinicaltrials.gov.au/resour ces-clinical-trials-australia

The Australian Government is strengthening and reforming the operating environment for clinical trials and research as a national priority, with the goal of making it easier for patients, researchers

Government initiatives to support this include the:

and sponsors to participate in and conduct trials.

- Proposed National One Stop Shop for Clinical Trials and Health Related Human Research Approvals (National One Stop Shop), a national, streamlined platform
- Proposed National Clinical Trials Front Door, a central access point
- National Clinical Trials Governance Framework a nationally consistent accreditation which embeds clinical trials into routine health service provision of health services undertaking trials



A searchable clinical trials registry accessible to the public www.anzctr.org.au/TrialSearch

### State government support for clinical trials





#### Connection to:

- Investigators and sites
- CROs, CMOs, Research Support Services
- NSW Health services eg: Biobank & Pathology
- Information and guidance on clinical trial delivery specific to Australia

#### Assistance with:

- Ethics & governance
- Regulatory matters
- Finance



### Victorian Clinical Trials *Gateway,* provides:

- Connections to Victorian clinical trial sites, contract research organisations and professional services
- Regional advice services
- Understanding core capabilities





### Queensland Clinical Trials Coordination Unit (QCTCU), services include:

- Clinical Trial Liaison Service single point of contact for sponsors to find a site for a clinical trial, or to locate service providers
- Research Ethics and Governance Service – provides advice and direction on ethical and governance issues
- Intellectual Property and Commercialisation Service – supports translation of research




### South Australian clinical trials portal, includes:

- Information on conducting clinical trials in South Australia including information for researchers, for participants and sponsors
- List of clinical trial provides
- Support services



### A sophisticated medical research environment





1,342

medical technology and pharmaceutical companies



152

ASX-listed life sciences companies



>58

world-class medical research institutes



>40

universities focusing on clinical research



>50

clinical trial networks



>50

biobanks



73,000

people employed in research and MTP sector



### Quality data from Australian clinical trials is accepted in key jurisdictions




Data from studies conducted in Australia can be used to support international regulatory applications, including the US FDA and the European Medicines Agency (EMA)




Clinical trials conducted in Australia do not require US FDA Investigational New Drug (IND) application approval

## Clinical trials by therapy area in Australia CY2015-19



Australia host 5% of global sponsored industry trials every year



In 2021, Australia
accounted for 11%
of ongoing clinical
trials investigating
regenerative medicine

Australia's Clinical Trials Ecosystem



#### **Linear Clinical Research**

has a purpose-built phase 1 facility, specialising in first-in-human, through to phase 4 clinical trials. The facility has strong connections 3 major hospitals enabling patient recruitment as well as collaboration opportunities with specialised physicians across many therapeutic areas.

LuinaBio is a contract manufacturing organisation with GMP capabilities for manufacturing: recombinant proteins and vaccines, live Biotherapeutics, materials for pre-clinical, clinical and market, and aerobic and strictly anaerobic microorganisms

Australian Clinical Labs - Specialised Trials offers a dedicated pathology approach to Phase I-

QLD

Queensland

VIC

**New South Wales** 

Victoria

NSW

South Australia

SA

offers a dedicated pathology approach to Phase I-IV clinical trials, for clinical research, pharmaceutical and biotechnology clients.



VIC

NSW Health State-wide Biobank is the largest biobank in the Southern Hemisphere and has capacity to collect, process and store three million human biospecimens.

Mobius Medical is a boutique CRO with almost a decade of experience working predominantly with startup medical device and pharmaceutical companies



WA

Western Australia

**Southern Oncology Clinical Research Unit (SOCRU)** is a leading-edge research facility and focusses on conducting early phase cancer trials, across a variety of interventions.

Melbourne Children's Trial Centre (MCTC) is a

unique collaboration between the Royal Children's Hospital, Murdoch Children's Research Institute and University of Melbourne working in a wide range of indications, including cancer

**Nucleus Network** is Australia's largest Phase 1 clinical research organization with facilities in both the US and Australia



### Biopharmaceutical Manufacturing

#### Australia is developing infrastructure for scaling biomedical product manufacturing



### Specialised advanced manufacturing infrastructure

- CSIRO Advanced Biologics Manufacturing Facility
- Westmead viral vector facility
- National Biologics Facility



An established health ecosystem with end-to-end, research and clinical support capabilities.



**Established advanced manufacturing** infrastructure to optimise and accelerate production of complex biopharmaceuticals.



### Medical product manufacturing is a key priority for Australia.

Funding initiatives are established by Commonwealth, including the National Reconstruction Fund, and State governments to strengthen Australia's manufacturing capability.







Speed

Rapid approvals and robust regulatory framework



Clinical trial process allows flexibility without compromising quality



Good Clinical Practice (GCP) standards ensure research quality




Simplification of clinical trial delivery by removing tariffs on clinical trial kits and placebos



World leading intellectual property (IP) system


### Streamlined Clinical Trials Notification (CTN) Scheme



reviews and approves the scientific and safety concerns for the clinical trial



### Cost-effective



Reports show Australia is

28%


cheaper than the US before tax incentives, and

60%

cheaper after tax incentives, for early-phase clinical trials

### Cost-effective

Favourable exchange rate and a generous R&D tax incentive boosts Australia's attractiveness






Companies with an annual aggregated turnover of less than A\$20 million receive a **refundable** tax offset, equal to their corporate tax rate plus an 18.5% premium



Companies with an annual aggregated turnover of more than A\$20 million receive a non-refundable tax offset and depends on intensity of the R&D expenditure as a proportion of total expenditure for the year.

- R&D intensity up to 2% receives a tax offset equal to the company tax rate plus 8.5% premium.
- Additional R&D intensity above 2% receives a tax offset equal to the company tax rate plus 16.5% premium.

<sup>\*</sup> Depending on turnover threshold corporate tax rate is either 25% (for small-medium businesses) or 30%.





Investigators, clinical networks and trial facilities of a global standing



Globally recognised key opinion leaders in major therapeutic areas



Contract manufacturing capabilities to support clinical trials



Quality data recognised in key markets, such as the US and EU



An ethnically diverse population



Seasonal differences



Use of digital expertise and analytics in patient recruitment

### Find out more

AusBiotech

ausbiotech.org

**Australian Clinical Trials** 

australianclinicaltrials.gov.au

Australian Clinical Trial Handbook

tga.gov.au/publication/australian-clinical-trial-handbook

Good Clinical Practice Inspection
Program

tga.gov.au/resources/publication/publications/ich-guideline-good-clinical-practice

**MTPConnect** 

mtpconnect.org.au/
Australia's Clinical Trials Sector (2021)

**Medicines Australia** 

medicinesaustralia.com.au

Medical Research Future Fund


<u>health.gov.au/our-work/medical-research-future-fund</u>

**National Statement** 

nhmrc.gov.au/about-us/publications/national-statementethical-conduct-human-research-2007-updated-2018



### How Austrade can help



### Simone Greulich | Investment Director Frankfurt

Austrade

T+49 (69) 055 8204

Simone.Greulich@austrade.gov.au | austrade.gov.au

### Nur Sidki Gomez | Senior Investment Adviser

Austrade

T+61 423 040 484

Nur.Sidki-Gomez@austrade.gov.au | austrade.gov.au

### Katherine Martin | Investment Adviser

Austrade

T+613 9648 3268

Katherine.Martin@austrade.gov.au | austrade.gov.au



## Contact us

for more information

www.austrade.gov.au